UBS Group AG Increases Position in uniQure N.V. $QURE

UBS Group AG increased its stake in shares of uniQure N.V. (NASDAQ:QURE) by 139.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 491,454 shares of the biotechnology company’s stock after buying an additional 286,465 shares during the quarter. UBS Group AG’s holdings in uniQure were worth $11,760,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. Jones Financial Companies Lllp grew its holdings in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 533 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after buying an additional 627 shares during the last quarter. FNY Investment Advisers LLC grew its holdings in shares of uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares during the last quarter. Finally, CIBC Private Wealth Group LLC purchased a new stake in shares of uniQure during the third quarter valued at $50,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on QURE shares. HC Wainwright lowered their price target on shares of uniQure from $70.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Chardan Capital upped their price target on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, Barclays lowered their price target on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.83.

Insider Activity

In other uniQure news, CFO Christian Klemt sold 12,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $108,720.00. Following the completion of the transaction, the chief financial officer owned 226,581 shares in the company, valued at approximately $2,052,823.86. This represents a 5.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Walid Abi-Saab sold 45,000 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the completion of the transaction, the insider owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. This trade represents a 20.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 94,396 shares of company stock worth $1,850,434. 4.79% of the stock is currently owned by insiders.

uniQure Price Performance

NASDAQ:QURE opened at $27.05 on Friday. The firm’s fifty day moving average is $18.31 and its two-hundred day moving average is $23.59. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -7.77 and a beta of 0.87. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Research analysts expect that uniQure N.V. will post -3.68 EPS for the current year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.